Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

Earlier this year, a new drug was recommended on the NHS in England and Wales for the first time for patients aged 12 and over with severe alopecia areata. Alopecia is caused by the immune system ...

Ritlecitinib is under clinical development by Pfizer and currently in Phase II for Celiac Disease ... Litfulo is indicated for the treatment of Alopecia areata for adults and children aged 12 years or ...

The drug had been turned down on cost grounds ... Lynn Clay, Specialty Care Lead, Pfizer UK, said: 'Alopecia areata can have a psychological impact on adults and adolescents living with the ...

Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year. Pfizer’s ...

A drug which it is hoped could help people living ... It is for treating severe alopecia areata in people who are aged 12 and over. Last month Megan McCready, who supports young people going ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the ...

Ritlecitinib is under clinical development by Pfizer and currently in Phase II for Keloids ... Litfulo is indicated for the treatment of Alopecia areata for adults and children aged 12 years or older, ...

LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire / -- The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.